A Randomized Trial Of The Electronic Lung Cancer Symptom Scale For Quality-Of-Life Assessment In Patients With Advanced Non-Small-Cell Lung Cancer

Introduction Improving health-related quality of life (HRQoL) is a key goal of systemic therapy in advanced lung cancer, although routine assessment remains challenging. We analyzed the impact of a real-time electronic HRQoL tool, the electronic Lung Cancer Symptom Scale (eLCSS-QL), on palliative care (PC) referral rates, patterns of chemotherapy treatment, and use of other supportive interventions in patients with advanced non-small-cell lung cancer (Nsuc) receiving first-line chemotherapy.Methods Patients with advanced NSCLC starting first-line chemotherapy were randomized to their oncologist receiving or not receiving their eLCSS-QL data before each clinic visit. Patients completed the eLCSS-QL at baseline, before each chemotherapy cycle, and at subsequent follow-up visits until disease progression. Prospective data about the PC referral rate, HRQoL, and use of other supportive interventions were collected.Results For the 95 patients with advanced NSCLC who participated, oncologists received real-time eLCSS-QL data for 44 (eLCSS-QL arm) and standard clinical assessment alone for 51 (standard arm). The primary endpoint, the PC referral rate, was numerically higher, but statistically similar, for patients in the eLCSS-QL and standard arms. The HRQoL scores over time were not significantly different between the two study arms.Conclusions The eLCSS-QL is feasible as a tool for use in routine clinical practice, although no statistically significant effect of its use was demonstrated in our study. Improving access to supportive care through the collection of patient-reported outcomes and HRQoL should be an important component of care for patients with advanced lung cancer.